CNM-Au8 is a suspension of clean-surfaced, faceted, gold nanocrystals that promotes remyelination and neuroprotection by catalysing nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP) production and by reducing oxidative stress. Treatment effects are evaluated using high-resolution 31P-magnetic resonance spectroscopy (31P-MRS). With this quantitative technique, bioenergetic metabolites can be monitored, as well as phospholipid and myelin precursors.
Preliminary target engagement data from 2 ongoing open-label imaging trials were presented: REPAIR-MS and REPAIR-PD. Treatment consisted of CNM-Au8 30 mg/day. 7T 31P-MRS was conducted at baseline and after 12-16 weeks of treatment. Results of 4 completers with MS and 6 with PD were available.
For key bioenergetic markers, percentage change from baseline at the end-of-study visit highly correlated with baseline levels. Whole-brain baseline NAD levels below the mean significantly increased at end-of-study visit. However, baseline NAD levels higher than the mean normalised to mean baseline levels. These dynamics were not only seen for total NAD levels (r2=0.6384; P=0.0056), but also for β-ATP (r2=0.8723; P<0.0001), and several other 31P-metabolites.
According to the authors, these observations indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics. Full analyses will be conducted once the 2 trials are completed. Another ongoing study, called VISIONARY-MS, will further explore the possible neuroprotective effects of the brain metabolic homeostasis observed with CNM-Au8 treatment.
- Ren J, et al. Effects of nanocatalysis on CNS bioenergetic markers in patients treated with CNM-Au8: Interim results from two Phase 2 31Phosphorous imaging studies. MSVirtual 2020, P0206.
© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution – NonCommercial (CC BY-NC 4.0)
Posted on
Previous Article
« Retinoid-X receptor agonist promotes remyelination Next Article
Masitinib: a first-in-class TKI as treatment of progressive MS »
« Retinoid-X receptor agonist promotes remyelination Next Article
Masitinib: a first-in-class TKI as treatment of progressive MS »
Table of Contents: MS Virtual 2020
Featured articles
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles

June 16, 2021
Dysmetabolism may drive MS progression
December 9, 2021
Personality trait alterations in MS patients
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy